H.R. 4374 · 115th Congress
To amend the Federal Food, Drug, and Cosmetic Act to authorize additional emergency uses for medical products…
Full title
To amend the Federal Food, Drug, and Cosmetic Act to authorize additional emergency uses for medical products to reduce deaths and severity of injuries caused by agents of war, and for other purposes.
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Became law without a recorded vote. It passed by voice vote or unanimous consent, which don't record how each member voted.
R
WaldenSponsorNo cosponsors.
- House Introduced Nov 13, 2017
- House Passed Nov 15, 2017
- Senate Passed Nov 16, 2017
- President To the President Nov 30, 2017
- President Signed Dec 12, 2017
The bill repeals provisions of the National Defense Authorization Act for Fiscal Year 2018 that allow DOD, rather than the FDA, to authorize the emergency use of an unapproved product under similar circumstances.
What it does: CRS summary · Public Law · Dec 12, 2017
(This measure has not been amended since it was introduced. The expanded summary of the House passed version is repeated here.)
(Sec. 1) This bill amends the Federal Food, Drug, and Cosmetic Act to allow the Food and Drug Administration (FDA) to authorize the emergency use of an otherwise unapproved medical product if the Department of Defense (DOD) determines that there is a military emergency involving an agent that may cause imminently life-threatening and specific risk to U.S. forces. If a military emergency is determined to exist, the bill allows DOD to request that the FDA expedite certain procedures for approving medical products that would be reasonably likely to diagnose, prevent, treat, or mitigate such risk. The FDA must take specified actions to facilitate such a request by DOD.
The bill repeals provisions of the National Defense Authorization Act for Fiscal Year 2018 that allow DOD, rather than the FDA, to authorize the emergency use of an unapproved product under similar circumstances.
Unless DOD determines such meetings to be unnecessary, the FDA shall meet with DOD: (1) semi-annually to conduct a full review of relevant medical products in the DOD portfolio; and (2) quarterly to discuss the development status of regenerative medicine advanced therapy, blood, and vaccine medical products and projects that DOD prioritizes.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: To amend the Federal Food, Drug, and Cosmetic Act to authorize additional emergency uses for medical products to reduce deaths and severity of injuries caused by agents of war, and for other purposes.
Latest action (Dec 12, 2017): Signed by President.
Policy area: Health · Origin: House · Introduced: Nov 13, 2017
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
- House Introduced Nov 13, 2017
- House Passed Nov 15, 2017
- Senate Passed Nov 16, 2017
- President To the President Nov 30, 2017
- President Signed Dec 12, 2017
No recorded floor vote found.